DermTech

United States
San Diego, California, United States, 92037

Company profile

DermTech company profile

DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego. The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).

Business identity

Contact email
[email protected]
Phone number
+1 858 450 4222
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
1996-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
11
Total equity funding
$257.4M
Last funding
Post IPO Equity / $143.7M / 2021-01-06
Last equity funding
Post IPO Equity / $143.7M
Investors
3
Lead investors
1
Founders
1
Articles
100
Exited on
2019-08-30

Founders and investors

Founders

John Dobak

Lead investors

HLM Venture Partners

Investors

HLM Venture PartnersTCA Venture GroupWestern States Investment Group